公开(公告)号：US20240325538A1

公开(公告)日：2024-10-03

申请号：US18254167

申请日：2021-11-25

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Zhou HE ,  Tiantian LI ,  Yongchao SHEN ,  Haibin CHEN ,  Chen HUANG ,  Fuhui XU

IPC: A61K39/00 ,  A61P35/00 ,  C12N5/0783

CPC classification number: A61K39/464499 ,  A61K39/4611 ,  A61P35/00 ,  C12N5/0636 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2309 ,  C12N2501/231 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/515 ,  C12N2501/52 ,  C12N2502/30

Abstract: A culture composition for expanding a TIL, containing IL-2, IL-7, IL-15, and an immune checkpoint antibody or an antigen-binding fragment thereof. The immune checkpoint antibody comprises any one or more of a PD-1 antibody, a CTLA-4 antibody, a LAG-3 antibody, a TIM-3 antibody, a TIGIT antibody, and a BTLA antibody. The present invention further relates to a TIL expanding culture medium, a method for preparing a TIL population, and a pharmaceutical composition. In the culture composition, cell proliferation and activity are ensured while greatly reducing the used amount of IL-2, and IL-2 treatment is removed after infusing the TILs obtained using the culture composition into a patient so as to reduce side effects; moreover, no feeder cells are used in an expansion process, exogenous pollution is reduced and the manufacturing process is simplified, the manufacturing costs reduced, and the manufacturing time shortened.

公开(公告)号：US20230383268A1

公开(公告)日：2023-11-30

申请号：US18248865

申请日：2021-10-12

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Fuhui XU ,  Chen HUANG ,  Xingming MA ,  Tianyi LIU ,  Xiaochun GUO

IPC: C12N9/12 ,  C12N15/85 ,  C12N15/113 ,  C12N5/0783 ,  A61K48/00

CPC classification number: C12N9/1241 ,  C12N15/85 ,  C12N15/113 ,  C12N5/0636 ,  A61K48/00 ,  C12N2510/00 ,  C12N2800/90 ,  C12N2830/50

Abstract: Provided is a nucleic acid construct, including the following elements: a transposon 3′ terminal repeat, first poly A sequence, an insulator sequence having a transcription termination function, a transposon 5′ terminal repeat, a transposase coding sequence, and a promoter that controls the expression of the transposase. Also provided are a host cell or pharmaceutical composition including said nucleic acid construct, and a use thereof.

公开(公告)号：US20230226111A1

公开(公告)日：2023-07-20

申请号：US18000122

申请日：2021-05-28

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Zhou HE ,  Xingming MA ,  Tiantian LI ,  Chen HUANG

IPC: A61K35/17 ,  C12N5/0783 ,  A61P35/00

CPC classification number: A61K35/17 ,  C12N5/0636 ,  A61P35/00 ,  C12N2501/2301 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2309 ,  C12N2501/231 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/51 ,  C12N2501/52

Abstract: A seed cell medium of a tumor-infiltrating lymphocyte and an application thereof. The medium contains a cell culture component, a cell factor, and an immune checkpoint antibody or an antigen-binding fragment thereof. The cell factor includes IL-2; an immune checkpoint includes PD-1, LAG-3, TIGIT, and/or CTLA-4; and the cell culture component is a serum medium or a serum-free medium. The seed cell medium accelerates a culture of a seed cell of the tumor-infiltrating lymphocyte and shortens the amplification time required by the tumor-infiltrating lymphocyte.

公开(公告)号：US20250049920A1

公开(公告)日：2025-02-13

申请号：US18710620

申请日：2022-11-15

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Ying ZHOU ,  Chao WANG ,  Chen HUANG

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705

Abstract: Provided is a membrane surface protein containing a GPI anchor region. Specifically, provided are a fusion protein comprising a functional domain and a GPI anchor region, and the use thereof. The fusion protein can effectively activate and proliferate immune cells, and improve the effector function of immune cells.

公开(公告)号：US20240238271A1

公开(公告)日：2024-07-18

申请号：US18254171

申请日：2021-11-25

Applicant: SHANGHAI JUNCELL THERAPEUTICS CO., LTD.

Inventor： Huajun JIN ,  Zhou HE ,  Tiantian LI ,  Yongchao SHEN ,  Haibin CHEN ,  Chen HUANG

IPC: A61K31/4706 ,  A61K9/00 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/4706 ,  A61K9/0019 ,  A61K45/06 ,  A61P35/00

Abstract: A pharmaceutical composition, containing chloroquine or a derivative thereof and a tumor cell killing agent, and a pharmaceutically acceptable excipient. Also provided is a use of chloroquine or a derivative thereof in preparation of a medication for treating a tumor.